ESMO Immuno-Oncology Congress 2025

Save the date for the ESMO Immuno-Oncology Congress 2025, taking place from 10 until 12 December 2025 as an onsite event in London, UK, as well as online.

This international event provides valuable knowledge: from basic science to translational research and clinical development, cutting-edge science, and excellent networking opportunities.

Take part in this meeting to learn, share your research and expertise and connect with the stakeholders that are making a difference in the field.

The ESMO Immuno-Oncology Congress 2025 will take place from 10 to 12 December 2025 in London, United Kingdom, with sessions available also through a dedicated platform.

Registration includes:

• Participation in scientific and educational sessions
• Opportunities to network with speakers, faculty and peers
• Access to the poster area
• Interaction with industry partners in the exhibition area
• Participation in the Industry Satellite Symposia
• Live-streamed sessions and sessions on-demand on the virtual congress platform
• Access to the meeting resources on OncologyPRO after the event
• The ESMO Daily Reporter
• Coffee breaks and lunches

Registration fees and deadlines

Individual registration will remain open for the duration of the congress. The ESMO Congress Secretariat must receive one completed registration per participant and the corresponding payment in EUR by the given deadlines.

ESMO membership must be active ten (10) working days prior to the registration, to be eligible for the reduced member registration fee. Please visit the membership pages on esmo.org to check eligibility criteria, benefits, and to complete the membership application.

The ESMO Immuno-Oncology Congress 2025 programme is online!

Learning objectives

• Access immersion sessions in immunobiology and immuno-oncology translational research insights
• Review state of the art, checkpoint inhibitor-based therapeutic strategies in immuno-oncology
• Understand recent developments in immune modulation, including tumour microenvironment, immunometabolism, epigenetics and cell signalling
• Connect with Industry and independent investigators for an overview of research and development in immuno-oncology, including cellular therapies, vaccines and immune modulators, intratumoural immunotherapy and multispecific constructs

Accreditation

ESMO-MORA: The ESMO Immuno-Oncology 2025 programme will be submitted for ESMO-MORA category 1 points accreditation. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.